Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
复制标题
DOI：
10.1182/blood.v70.2.587.bloodjournal702587
复制
发表时间：
1987-08
期刊：
影响因子：
20.3
通讯作者：
S. Forman;M. O'donnell;A. Nademanee;D. Snyder;P. Bierman;G. M. Schmidt;J. Fahey;A. Stein;P. Parker;K. Blume
中科院分区：
文献类型：
--
作者：
S. Forman;M. O'donnell;A. Nademanee;D. Snyder;P. Bierman;G. M. Schmidt;J. Fahey;A. Stein;P. Parker;K. Blume
我们报告了10例费城染色体阳性急性淋巴细胞白血病患者的异基因骨髓移植治疗结果。6名患者在移植后6至30个月（中位数19个月）内存活且健康。4例患者死于移植相关并发症。考虑到与这种疾病相关的不良预后，如果有合适的骨髓供体，骨髓消融后进行同种异体或同基因骨髓移植可能是首选的治疗方式。
We report the treatment outcome of allogeneic bone marrow transplantation in ten patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Six patients are alive and well for 6 to 30 months (median 19 months) after transplantation. Four patients died with transplant related complications. In view of the poor prognosis associated with this disease, marrow ablation followed by allogeneic or syngeneic marrow grafting may be the preferred treatment modality if a suitable marrow donor is available.